X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Elder Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ELDER PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
ADCOCK INGRAM
Jun-14
ELDER PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs380381-   
Low Rs188275-   
Sales per share (Unadj.) Rs491.2113.4-  
Earnings per share (Unadj.) Rs-3.2-28.6-  
Cash flow per share (Unadj.) Rs14.4-23.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.589.0-  
Shares outstanding (eoy) m20.54168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.62.9 20.0%   
Avg P/E ratio x-89.3-11.5 777.4%  
P/CF ratio (eoy) x19.7-13.9 -142.3%  
Price / Book Value ratio x0.83.7 20.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,83355,398 10.5%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m2,1793,477 62.7%   
Avg. sales/employee Rs ThNM4,459.9-  
Avg. wages/employee Rs ThNM809.9-  
Avg. net profit/employee Rs ThNM-1,123.8-  
INCOME DATA
Net Sales Rs m10,08919,146 52.7%  
Other income Rs m257134 191.4%   
Total revenues Rs m10,34619,280 53.7%   
Gross profit Rs m-792-3,318 23.9%  
Depreciation Rs m361826 43.7%   
Interest Rs m2,756519 531.5%   
Profit before tax Rs m-3,653-4,529 80.7%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125283 44.2%   
Profit after tax Rs m-65-4,824 1.4%  
Gross profit margin %-7.8-17.3 45.3%  
Effective tax rate %-3.4-6.2 54.8%   
Net profit margin %-0.6-25.2 2.6%  
BALANCE SHEET DATA
Current assets Rs m9,24014,023 65.9%   
Current liabilities Rs m9,9987,890 126.7%   
Net working cap to sales %-7.532.0 -23.4%  
Current ratio x0.91.8 52.0%  
Inventory Days Days46111 41.8%  
Debtors Days Days60124 48.4%  
Net fixed assets Rs m10,1248,174 123.9%   
Share capital Rs m20689 231.4%   
"Free" reserves Rs m5,5820-   
Net worth Rs m7,73415,028 51.5%   
Long term debt Rs m4,8895,281 92.6%   
Total assets Rs m22,88228,389 80.6%  
Interest coverage x-0.3-7.7 4.2%   
Debt to equity ratio x0.60.4 179.9%  
Sales to assets ratio x0.40.7 65.4%   
Return on assets %11.8-15.2 -77.5%  
Return on equity %-0.8-32.1 2.6%  
Return on capital %22.3-19.8 -112.6%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Net fx Rs m1810-   
CASH FLOW
From Operations Rs m11,7541,634 719.2%  
From Investments Rs m-561-502 111.7%  
From Financial Activity Rs m-6,7624,793 -141.1%  
Net Cashflow Rs m4,4325,925 74.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.26 Rs / ZAR

Compare ELDER PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare ELDER PHARMA With: JUBILANT LIFE SCIENCES  MERCK LTD  AUROBINDO PHARMA  SANOFI INDIA  ORCHID PHARMA LTD  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS